J. Safra Sarasin Holding AG Invests $1.09 Million in Insmed, Inc. $INSM

J. Safra Sarasin Holding AG acquired a new stake in Insmed, Inc. (NASDAQ:INSM) in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund acquired 7,557 shares of the biopharmaceutical company’s stock, valued at approximately $1,088,000.

Other hedge funds have also recently bought and sold shares of the company. Vanguard Personalized Indexing Management LLC boosted its holdings in Insmed by 18.2% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 9,552 shares of the biopharmaceutical company’s stock valued at $1,376,000 after acquiring an additional 1,471 shares during the period. Whittier Trust Co. of Nevada Inc. increased its stake in Insmed by 169.7% during the third quarter. Whittier Trust Co. of Nevada Inc. now owns 240 shares of the biopharmaceutical company’s stock worth $38,000 after purchasing an additional 151 shares during the period. Sagespring Wealth Partners LLC lifted its position in shares of Insmed by 8.0% during the third quarter. Sagespring Wealth Partners LLC now owns 2,729 shares of the biopharmaceutical company’s stock worth $393,000 after purchasing an additional 201 shares in the last quarter. Strs Ohio boosted its stake in shares of Insmed by 590.3% in the third quarter. Strs Ohio now owns 29,454 shares of the biopharmaceutical company’s stock valued at $4,242,000 after purchasing an additional 25,187 shares during the period. Finally, Cravens & Co Advisors LLC acquired a new position in shares of Insmed in the third quarter valued at approximately $291,000.

Insiders Place Their Bets

In other Insmed news, Director Elizabeth M. Anderson sold 10,000 shares of the stock in a transaction that occurred on Friday, November 14th. The shares were sold at an average price of $195.87, for a total value of $1,958,700.00. Following the transaction, the director directly owned 63,729 shares in the company, valued at $12,482,599.23. This represents a 13.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 87,290 shares of the firm’s stock in a transaction that occurred on Friday, January 2nd. The stock was sold at an average price of $175.20, for a total transaction of $15,293,208.00. Following the sale, the insider directly owned 41,754 shares in the company, valued at approximately $7,315,300.80. The trade was a 67.64% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 296,799 shares of company stock worth $54,296,286. 3.00% of the stock is currently owned by company insiders.

Insmed Stock Performance

Shares of INSM stock opened at $155.89 on Thursday. The company has a current ratio of 4.63, a quick ratio of 4.34 and a debt-to-equity ratio of 0.59. The firm has a fifty day moving average price of $181.91 and a 200 day moving average price of $157.83. The company has a market cap of $33.25 billion, a P/E ratio of -25.18 and a beta of 1.08. Insmed, Inc. has a 12 month low of $60.40 and a 12 month high of $212.75.

Insmed (NASDAQ:INSM) last posted its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.35) by ($0.40). The business had revenue of $142.34 million during the quarter, compared to analyst estimates of $114.33 million. Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm’s quarterly revenue was up 52.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($1.27) earnings per share. Sell-side analysts predict that Insmed, Inc. will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on INSM. Rothschild & Co Redburn initiated coverage on shares of Insmed in a report on Thursday, December 4th. They set a “buy” rating and a $263.00 target price on the stock. Wedbush set a $203.00 price objective on Insmed in a research report on Thursday, December 18th. HC Wainwright decreased their target price on Insmed from $240.00 to $230.00 and set a “buy” rating for the company in a report on Thursday, December 18th. Truist Financial set a $205.00 target price on Insmed in a research note on Monday, January 12th. Finally, UBS Group cut their price target on Insmed from $223.00 to $215.00 and set a “buy” rating on the stock in a report on Tuesday, January 6th. Three analysts have rated the stock with a Strong Buy rating, twenty have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $205.83.

Insmed Profile

Insmed Incorporated is a biopharmaceutical company focused on developing and commercializing therapies for patients with rare and serious diseases, with a particular emphasis on difficult-to-treat pulmonary infections. Headquartered in Bridgewater, New Jersey, the company concentrates its research and development efforts on targeted drug delivery technologies and novel formulations intended to improve clinical outcomes for patients who have limited treatment options.

The company’s principal marketed product is ARIKAYCE (amikacin liposome inhalation suspension), an inhaled liposomal formulation of the antibiotic amikacin that is approved by the U.S.